Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Inclusion Criteria: * Must be \>- 18 years old, with a life expectancy \> 8 weeks * Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma * Must submit an unstained paraffin block or slides from surgical procedure * Patients without prior treatment and with prior diagnosis of lower-grade gliomas that have been upgraded to GBM after repeated resection allowed * At least 21 days since cranial MRI or contrast CT scan OR ≥ 96 hours since cranial MRI or contrast CT scan for patients who underwent surgical resection * Measurable or assessable disease * Voluntary written informed consent obtained before performance of any study related procedure not part of normal medical care. * Karnofsky performance status \> 60% * White Blood Count (WBC) ≥ 3,000/mm\^3 * absoulte neutrophil count(ANC) ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 10 g/dL (transfusion allowed) * Bilirubin \< 2.5 times upper limit of normal (ULN) * serum glutamic-oxaloacetic transaminase (SGOT) \< 2.5 times ULN * Creatinine \< 1.5 mg/dL * Creatinine clearance ≥ 20 mL/minute * Serum sodium \> 130 mmol/L * Negative pregnancy test * Fertile patients must use effective contraception * Patients on Enzyme-Inducing Antiepileptic Drugs (EIAED) must be transitioned to non- EAIED for ≥ 2 weeks * Concurrent full-dose warfarin or its equivalent (e.g., unfractionated and/or low molecular weight heparin) allowed Exclusion Criteria: * peripheral neuropathy ≥ grade 2 * Myocardial infarction within the past 6 months * New York Heart Association (NYHA) class III or IV heart failure * Uncontrolled angina * Severe uncontrolled ventricular arrhythmias * Electrocardiographic evidence of acute ischemia or active conduction system abnormalities * hypersensitivity to bortezomib, boron, or mannitol * serious medical or psychiatric illness that would interfere with study participation including, but not limited to, any of the following: * Ongoing or active infection requiring IV antibiotics * Psychiatric illness and/or social situations that would limit compliance with study requirements * Disorders associated with a significant immunocompromised state (e.g., HIV, systemic lupus erythematosus) * history of stroke within the past 6 months * other malignancy within the past 3 years except completely resected basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy (i.e., cervical cancer), or low-risk prostate cancer after curative therapy * significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy * disease that will obscure toxicity or dangerously alter drug metabolism * viral hepatitis (HBV surface antigen positive) or active hepatitis C infection * Prior or concurrent corticosteroids, automated external defibrillator, analgesics, and other drugs to treat symptoms or prevent complications allowed * concurrent investigational drugs that must be stopped at least 4 months prior to therapy. * prior radiotherapy to the brain * prior cytotoxic or noncytotoxic drug therapy or experimental drug therapy (including chemotherapy, hormonal therapy, or immunotherapy) directed against the brain tumor * prior polifeprosan 20 with carmustine implant (Gliadel wafer) * concurrent stereotactic radiosurgery or brachytherapy * concurrent sargramostim * concurrent inducers of CYP450 3A4 (e.g., enzyme-inducing anti-epileptic drugs \[EIAED\])